ATROPINE SULFATE INJECTION 0.5 MG / 5 ML — DIN 02426269
ATROPINE SULFATE 0.5 MG · LABORATOIRE AGUETTANT · Solution · wholesale supply in Canada
Health Canada status: MARKETED
What is ATROPINE SULFATE INJECTION?
ATROPINE SULFATE INJECTION 0.5 MG / 5 ML contains ATROPINE SULFATE 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02426269, held by LABORATOIRE AGUETTANT, supplied as Solution for Intravenous, Subcutaneous, Intramuscular administration. Health Canada currently lists it as marketed, status dated 26-Nov-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ATROPINE SULFATE INJECTION used for?
Antisialagogue; restore cardiac rate/arterial pressure during anesthesia; A-V heart block; hyperactive carotid sinus reflex; antidote for cholinergic drugs, organophosphorus, or mushroom poisoning.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Atropine cost around the world?
Atropine is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Iceland publishes a max wholesale; Lebanon publishes a public price (USD, Decision 119/1). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 2 | 20 | USD███.██ |
| Morocco | PPV (public price) | 4 | 6 | MAD███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Iceland | max wholesale | 4 | 4 | ISK███.██ |
| South Africa | single exit price | 4 | 4 | ZAR███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 2 | USD███.██ |
43 pack listings across 22 brand entries and 7 price bases, refreshed 05 Sep 2026. Ranges span every Atropine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Atropine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Atropine, across 19 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| LABORATOIRE AGUETTANT | 3 | 2 | ATROPINE SULFATE INJECTION | Sourceable in Canada |
| HIKMA CANADA LIMITED | 2 | 2 | ATROPINE INJECTION BP | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 2 | ATROPINE SULFATE INJECTION USP | Sourceable in Canada |
| HOSPIRA HEALTHCARE ULC | 4 | 0 | ATROPINE SULFATE INJ 0.3MG/ML, ATROPINE SULFATE INJ 0.4MG/ML, ATROPINE SULFATE INJ 0.6MG/ML, ATROPINE SULFATE INJ 1MG/ML | No marketed DIN |
| ALVEDA PHARMACEUTICALS INC | 2 | 0 | ATROPINE INJECTION BP 0.4MG/ML, ATROPINE INJECTION BP 0.6MG/ML | No marketed DIN |
| ASTRA PHARMA INC. | 2 | 0 | ATROPINE SULFATE INJ 0.4MG/ML, ATROPINE SULFATE INJ 0.6MG/ML | No marketed DIN |
| INTERNATIONAL MEDICATION SYSTEMS LTD. | 2 | 0 | ATROPINE SULFATE INJ 0.1MG/ML, ATROPINE SULFATE INJ 0.4MG/0.5ML | No marketed DIN |
| PFIZER CANADA ULC | 2 | 0 | ATROPINE SULFATE INJECTION USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.5 MG / 5 ML |
|---|---|
| Dosage form | Solution |
| Route | Intravenous, Subcutaneous, Intramuscular |
| Pack configuration (monograph) | Sterile, polypropylene pre-filled syringes in sterile blister packs. Each carton contains 10 pre-filled syringes. Sizes: 5 mL and 10 mL. |
| Storage | Store syringe in blister pack in original package between 15°C – 30°C. Avoid excessive heat. Protect from freezing. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Atropine |
|---|---|
| ATC code | A03BA01 |
| AHFS class | 48:08.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02426269 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2426269 |
| Brand name | ATROPINE SULFATE INJECTION |
| Generic / active ingredient | ATROPINE SULFATE 0.5 MG |
| Market authorization holder | LABORATOIRE AGUETTANT |
| Health Canada schedule | PRESCRIPTION |
| ATC code | A03BA01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A03BA |
| Current status | MARKETED |
| Status date | 26-Nov-2021 |
| Original market date | 2016-04-12 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
IV, IM, or SC. IV preferred for life-threatening cases. Adults: 0.4-0.6 mg. Bradyarrhythmias: 0.4-1 mg IV every 1-2 hours (max 2 mg). Pediatrics: 0.01-0.03 mg/kg IV.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Glaucoma, GI obstruction, pyloric stenosis, prostatic hypertrophy (except for pre-anesthetic use), and hypersensitivity to the drug or any ingredient.
Warnings and precautions
Highly potent; avoid overdosage. Children and elderly are more susceptible to CNS toxic effects (agitation, confusion). Caution in patients over 40 and those with chronic lung disease or fever.
Is Atropine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PFIZER CANADA ULC, last seen 20 Apr 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 19 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ATROPINE INJECTION BP | 0.4 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02432188 |
| ATROPINE INJECTION BP | 0.6 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02432196 |
| ATROPINE SULFATE INJECTION | 1 MG / 5 ML | SOLUTION | LABORATOIRE AGUETTANT | MARKETED | 02426277 |
| ATROPINE SULFATE INJECTION USP | .6 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 00392693 |
| ATROPINE SULFATE INJECTION USP | 0.4 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 00392782 |
| ATROPINE INJECTION BP 0.4MG/ML | 0.4 MG | SOLUTION | ALVEDA PHARMACEUTICALS INC | CANCELLED (UNRETURNED ANNUAL) | 02094681 |
| ATROPINE INJECTION BP 0.6MG/ML | 0.6 MG | SOLUTION | ALVEDA PHARMACEUTICALS INC | CANCELLED (UNRETURNED ANNUAL) | 02094703 |
| ATROPINE SULFATE INJ 0.1MG/ML | .1 MG | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | 00243515 |
| ATROPINE SULFATE INJ 0.3MG/ML | 0.3 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00497223 |
| ATROPINE SULFATE INJ 0.4MG/0.5ML | 0.8 MG | SOLUTION | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | 00243523 |
2 · Same class — other molecules in ATC A03BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Atropine | ATROPINE INJECTION BP · ATROPINE INJECTION BP 0.4MG/ML · ATROPINE INJECTION BP 0.6MG/ML · ATROPINE SULFATE INJ 0.1MG/ML · +7 more | 19 | 6 | Yes |
| Hyoscyamine | LEVSIN · LEVSIN DROPS 0.125MG/ML | 2 | 0 | Not in Canada |
| Belladonna Total Alkaloids | BELLADONE TCT | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A03B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A03BB | Belladonna Alkaloids Semisynt, Quater Ammonium Comp · Butylscopolamine | 6 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ATROPINE SULFATE INJECTION called?
The same molecule, Atropine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| ATROPINE | Latin | Lebanon |
| Atropine Minims | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.